AbbVie Showcases IBD Therapies at Digestive Disease Week Annual Meeting

AbbVie Showcases IBD Therapies at Digestive Disease Week Annual Meeting
North Chicago, Illinois based multinational biopharmaceutical company AbbVie presented 13 abstracts at the Digestive Disease Week (DDW) Annual Meeting held May 21-24, 2016, at San Diego, California. Abstracts presented addressed treatment developments for inflammatory bowel diseases (IBD) including adult and pediatric Crohn's disease, and ulcerative colitis. AbbVie and Boehringer Ingelheim also presented late-breaking data on the L-23p19 blocker risankizumab, formerly known as BI 655066, an investigational anti-IL-23 monoclonal biologic antibody that is the frontrunner biologic from Boehringer Ingelheim's Immunology research. AbbVie and Boehringer Ingelheim entered into a global collaboration agreement in March 2016 to develop and commercialize risankizumab, currently in Phase 2 development for the treatment of Crohn's disease, psoriatic arthritis and asthma, and in Phase 3 development as a psoriasis treatment. Research on AbbVie's HUMIRA (adalimumab) for the treatment of IBDs, including moderate to severe Crohn's disease in adult and pediatric patients, was also presented during the meeting, namely seven-year interim results from the ongoing PYRAMID post-marketing surveillance safety registry evaluating HUMIRA's safety profile in patients with moderate to severe Crohn's disease, and results of a long-term efficacy and safety analysis of HUMIRA in patients with moderate to severe pediatric Crohn's disease. AbbVie notes that HUMIRA is one of the most comprehensively studied biologics available, with more than 19 years of clinical trial experience under its belt (beginning in rheumatoid arthritis), and that the drug is currently being used to treat more than 989,000 patients worldwide, across all indications. "AbbVie is committed to continued research in gas
Subscribe or to access all post and page content.